Silverback Therapeutics, which is developing drugs that will only act at the site of disease, has closed a $47.5m round backed by Celgene.
Silverback Therapeutics, a US-based startup working on locally active medicines, has completed a $47.5m series A round featuring pharmaceutical firm Celgene.
Healthcare investment firm OrbiMed led the round, which included Alexandria Venture Investments, the venture capital branch of life sciences real estate investment trust Alexandria Real Estate Equities.
Silverback is developing therapies through its ImmunoTac platform for conditions such as cancer and fibrosis. The drugs will act at the site of a disease, meaning tissue elsewhere can be protected from…